Membrane-anchored IL-12 on the engineered T cells binds IL-12 receptors (including IL12RB2) on immune cells to activate them; the activated T/NK cells then kill CSV-expressing tumor cells via perforin/granzyme and IFN-gamma–mediated mechanisms. Cells expressing IL12RB2 are activated, not directly killed.